Given the various predictive roles for tumor grade, clinical stages, survival prognosis, molecular subtypes, gene mutation load, PD-L1/PD-1 expression levels, and treatment benefits for different immunotherapy strategies, the m6Ascore described in this study robustly confirmed an important role of m6A methylation modification patterns in bladder tumors, and this information could be utilized to guide immunotherapies in the future. This evidence concerns the gene PDCD1 and urinary bladder neoplasm.